Tools   Select Another Resource Report Type

https://ganjoho.jp/public/index.html

Portal provides information on Cancer Statistics in Japan. Official website operated by National Cancer Center for cancer information.

Proper citation: Cancer Information Service (RRID:SCR_024445) Copy   

•   Source: SciCrunch Registry

http://cancer.osu.edu/research/cancerresearch/sharedresources/ltb/Pages/index.aspx

The OSU Comprehensive Cancer Center Leukemia Tissue Bank Shared Resource (LTBSR) facilitates the successful translation of basic leukemia research to the clinical setting via an extensive repository of tissue samples and accompanying pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. The LTBSR, which is an NCI-sponsored biorepository, has more than 40,000 vials of cryopreserved viable cells and 13,000 vials of matched frozen plasma and/or serum samples from more than 4,000 patients treated for leukemia and other malignancies. Committed to furthering translational research efforts for OSUCCC - James members and the cancer research community, the LTBSR provides investigators with training and technical support as well as procurement, processing, storage, retrieval and distribution of clinical research materials. In many cases, the LTBSR serves as the central processing lab for multi-site trials in which the principal investigator is an OSUCCC - James member. The LTBSR's goals are to: * Provide a central collection, processing and a state-of-the-art repository for samples collected from leukemia patients treated on OSUCCC - James protocols, and * Provide materials to investigators involved in collaborative studies with OSU, who examine relevant cellular and molecular properties of leukemia and correlate these properties with clinical or population-based outcomes.

Proper citation: Ohio State Leukemia Tissue Bank (RRID:SCR_000529) Copy   

•   Source: SciCrunch Registry

http://pstiing.icr.ac.uk/

A publicly accessible knowledgebase about protein-protein, protein-lipid, protein-small molecules, ligand-receptor interactions, receptor-cell type information, transcriptional regulatory and signal transduction modules relevant to inflammation, cell migration and tumourigenesis. It integrates in-house curated information from the literature, biochemical experiments, functional assays and in vivo studies, with publicly available information from multiple and diverse sources across human, rat, mouse, fly, worm and yeast. The knowledgebase allowing users to search and to dynamically generate visual representations of protein-protein interactions and transcriptional regulatory networks. Signalling and transcriptional modules can also be displayed singly or in combination. This allow users to identify important "cross-talks" between signalling modules via connections with key components or "hubs". The knowledgebase will facilitate a "systems-wide" understanding across many protein, signalling and transcriptional regulatory networks triggered by multiple environmental cues, and also serve as a platform for future efforts to computationally and mathematically model the system behavior of inflammatory processes and tumourigenesis.

Proper citation: pSTIING (RRID:SCR_002045) Copy   

•   Source: SciCrunch Registry

http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/

Database to store and display somatic mutation information and related details and contains information relating to human cancers. The mutation data and associated information is extracted from the primary literature. In order to provide a consistent view of the data a histology and tissue ontology has been created and all mutations are mapped to a single version of each gene. The data can be queried by tissue, histology or gene and displayed as a graph, as a table or exported in various formats.
Some key features of COSMIC are:
* Contains information on publications, samples and mutations. Includes samples which have been found to be negative for mutations during screening therefore enabling frequency data to be calculated for mutations in different genes in different cancer types.
* Samples entered include benign neoplasms and other benign proliferations, in situ and invasive tumours, recurrences, metastases and cancer cell lines.

Proper citation: COSMIC - Catalogue Of Somatic Mutations In Cancer (RRID:SCR_002260) Copy   

•   Source: SciCrunch Registry

http://magi.cs.brown.edu/

A tool for annotating, exploring, and analyzing gene sets that may be associated with cancer.

Proper citation: Mutation Annotation and Genomic Interpretation (RRID:SCR_002800) Copy   

•   Source: SciCrunch Registry

http://www.karmanos.org/

Center for patient care, education and research on cancer. The institute focuses its research on prevention methods, early detection, treatment and finding cures.

Proper citation: Karmanos Cancer Institute (RRID:SCR_000508) Copy   

•   Source: SciCrunch Registry

https://seer.cancer.gov/csr/1975_2016/

Platform to report outlining trends in cancer statistics and methods to derive various cancer statistics from the Surveillance, Epidemiology, and End Results (SEER) program. Authoritative source for cancer statistics in the United States.

Proper citation: NCI SEER Cancer Statistics Review (RRID:SCR_024685) Copy   

•   Source: SciCrunch Registry

http://www.bwhct.nhs.uk/wmrgl/biobank-cehrb

The Central England Haemato-Oncology Research Biobank stores excess material from oncology samples referred for diagnostic testing and disease monitoring at the West Midlands Regional Genetics Laboratory (WMRGL). The bank is housed within the WMRGL. Types of material stored include viable cells, fixed cell suspensions, DNA, RNA / cDNA, and plasma. The material is made available to all cancer research groups both locally and nationally. Excess sample (mainly from blood and bone marrow) is stored from diagnostic patient material and from samples received throughout their disease course. The WMRGL serves a population of about 5.5 million and is the largest UK NHS genetic Lab. Due to the large patient population CEHRB is able to collate sufficient research material from all classifications of neoplastic haematological disorders including those that are rare.

Proper citation: Central England Haemato-Oncology Research Biobank (RRID:SCR_004637) Copy   

•   Source: SciCrunch Registry

http://dctd.cancer.gov/

Division of NCI that takes prospective cancer detection and treatment leads, facilitates their paths to clinical application, and expedites the initial and subsequent large-scale testing of new agents, biomarkers, imaging tests, and other therapeutic interventions (radiation, surgery, immunotherapy) in patients. DCTD, like all of NCI, supports many programs that could not be done without government funding - investigators supported by the division engage in scientifically sound, high-risk research that may yield great benefits for patients with cancer, but are too difficult or risky for industry or academia to pursue. This includes a particular emphasis on the development of distinct molecular signatures for cancer, refined molecular assays, and state-of-the-art imaging techniques that will guide oncologic therapy in the future. The division has eight major programs that work together to bring unique molecules, diagnostic tests, and therapeutic interventions from the laboratory bench to the patient bedside: * Cancer Diagnosis Program * Cancer Imaging Program * Cancer Therapy Evaluation Program * Developmental Therapeutics Program * Radiation Research Program * Translational Research Program * Biometrics Research Branch * Office of Cancer Complementary and Alternative Medicine

Proper citation: DCTD (RRID:SCR_004196) Copy   

•   Source: SciCrunch Registry

http://ccr.coriell.org/Sections/Collections/Wistar/?SsId=74

Collection of cell lines developed by Wistar scientists that includes a group of hybridomas that produce monoclonal antibodies that are useful in influenza research and vaccine development, melanoma cell lines derived from patients with diseases ranging from mild dysplasia to advanced metastatic cancer and a range of human endothelial cell lines.

Proper citation: Wistar Institute Collection at Coriell (RRID:SCR_004660) Copy   

•   Source: SciCrunch Registry

http://www.ngfn.de/en/start.html

The program of medical genome research is a large-scale biomedical research project which extends the national genome research net (NGFN) and will be funded by the federal ministry of education and research (BMBF) from 2008-2013. Currently the program includes two fields: * Research ** NGFN-Plus: With the aim on combating diseases that are central to health policy, several hundred researchers are systematically investigating the complex molecular interactions of the human body. They are organized in 26 Integrated Genome Research Networks. * Application ** NGFN-Transfer: The rapid transfer of results from medical genome research into medical and industrial application is the aim of the scientists from research institutes and biomedical enterprises that cooperate in eight Innovation Alliances. AREAS OF DISEASE * Cardiovascular disease * Cancer * Neuronal diseases * Infections and Inflammations * Environmental factors

Proper citation: National Genome Research Network (RRID:SCR_006626) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=31537&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented on April 4, 2014. Tissue Biobank collects samples from different types of cancers patients prospectively. Blood samples are being sent to KI Biobank for DNA extraction and storage. Number of sample donors: 611 (June 2010)

Proper citation: KI Biobank - Tissue Biobank (RRID:SCR_006043) Copy   

•   Source: SciCrunch Registry

http://biobankireland.com/

Biobank Ireland Trust promotes the development of an Irish Hospital Biobank Network to coordinate collection of small samples of cancer and normal tissue and coded patient data from those having a cancer operation. This will facilitate international molecular research collaborations, which may help identify the best treatment for each individual patient - personalized medicine. Biobank Ireland is promoting the development of a Hospital Biobank Network throughout the island of Ireland as a bridge between cancer research and care. This new infrastructure will facilitate large national and international translational research collaborations that will raise Ireland''s research profile and benefit those with cancer. Researchers will have online access to samples and to restricted patient data from participating hospitals and an equitable withdrawal process for scientifically and ethically approved projects. Important research results will be explained to the public. Other Objectives: * To facilitate (inter)national translational research collaborations that may lead to new tests and better, less toxic treatments for those with cancer * To enable molecular research on cancer tissue from clinical trials patients identify the best treatment for each individual patient ������??personalized medicine������?? * Researchers will have online access to samples and restricted patient data from participating hospitals, and a fair release process for scientifically and ethically approved projects * Biobank Ireland recognizes the need to have harmonization in biobanking around the world * Important research results will be explained to the public * Biobank Ireland will seek to have the hospital-based Biobank Network funded by government as standard of care

Proper citation: Biobank Ireland Trust (RRID:SCR_006430) Copy   

•   Source: SciCrunch Registry

http://www.nitrc.org/projects/tumorsim/

Simulation software that generates pathological ground truth from a healthy ground truth. The software requires an input directory that describes a healthy anatomy (anatomical probabilities, mesh, diffusion tensor image, etc) and then outputs simulation images.

Proper citation: TumorSim (RRID:SCR_002604) Copy   

•   Source: SciCrunch Registry

http://seer.cancer.gov/resources/

Portal provides SEER research data and software SEER*Stat and SEER*Prep. SEER incidence and population data associated by age, sex, race, year of diagnosis, and geographic areas can be used to examine stage at diagnosis by race/ethnicity, calculate survival by stage at diagnosis, age at diagnosis, and tumor grade or size, determine trends and incidence rates for various cancer sites over time. SEER releases new research data every Spring based on the previous November’s submission of data.

Proper citation: SEER Datasets and Software (RRID:SCR_003293) Copy   

•   Source: SciCrunch Registry

https://www.cancer.gov/about-cancer/treatment/drugs

Portal to find consumer friendly information about drugs for cancer and conditions related to cancer. The list is in alphabetical order by generic name and brand name.

Proper citation: NIH NCI list of FDA approved cancer drugs (RRID:SCR_021841) Copy   

•   Source: SciCrunch Registry

http://www.civm.duhs.duke.edu/

Biomedical technology research center dedicated to the development of novel imaging methods for the basic scientist and the application of the methods to important biomedical questions. The CIVM has played a major role in the development of magnetic resonance microscopy with specialized MR imaging systems capable of imaging at more than 500,000x higher resolution than is common in the clinical domain. The CIVM was the first to demonstrate MR images using hyperpolarized 3He which has been moved from mouse to man with recent clinical trials performed at Duke in collaboration with GE. More recently the CIVM has developed the molecular imaging workbench---a system dedicated to multimodality cardiopulmonary imaging in the rodent. Their collaborators are employing these unique imaging systems in an extraordinary range of mouse and rat models of neurologic disease, cardiopulmonary disease and cancer to illuminate the underlying biology and explore new therapies.

Proper citation: Center for In Vivo Microscopy (RRID:SCR_001426) Copy   

•   Source: SciCrunch Registry

http://ranchobiosciences.com/gse4922/

Curated data set of a study that investigated the expression profiles of 347 primary invasive breast tumors on Affymetrix microarrays. Three separate breast cancer cohorts were analyzed: 1) Uppsala (n=249), 2) Stockholm (n=58), 3) Singapore (n=40). The Uppsala and Singapore data can be accessed in GSE4922. The Stockholm cohort data can be accessed at GEO Series GSE1456.

Proper citation: GSE4922 (RRID:SCR_003557) Copy   

•   Source: SciCrunch Registry

http://www.yale.edu/herzongroup/Herzon_Lab/Home.html

My laboratory has created a family of natural product-inspired anticancer agents. We have evaluated our compounds at the Yale Center for Chemical Genomics, and they are exhibiting IC50 values in the low nM range against K562, HeLa, LnCAP, and HCT-116 lines. Their mechanism of action is unknown, although the natural products have been shown to cleave DNA. An evaluation of the natural products at the NCI has shown that they have a toxicity profile that is distinct from other known DNA damaging agents. We can readily access gram-quantities of these agents for further studies. We are looking for researchers who might find these compounds useful in medicinal applications, for example, for treatment of a specific cancer. We are capable of synthesizing new analogs, such as those incorporating a specific recognition or targeting element, and would be excited to pursue this avenue of research.

Proper citation: Herzon Lab (RRID:SCR_008850) Copy   

•   Source: SciCrunch Registry

http://firebrowse.org/

Portal provides access to cancer genomic data from variety of analyses: clinical, copy number, miR, miRseq, mRNA, mRNAseq, mutation and pathway analyses. Provides comprehensive suite of interdependent analyses of those data, including: correlations, clustering, and GISTIC and MutSigCV. Companion portal to the Broad Institute GDAC Firehose analysis pipeline, and was developed to cull and analyze data generated by The Cancer Genome Atlas (TCGA), which characterizes and identifies genomic patterns in human cancer models.

Proper citation: FireBrowse (RRID:SCR_026320) Copy   

•   Source: SciCrunch Registry